{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-007516","form_type":"8-K","ticker":"PDSB","cik":"0001472091","company_name":"PDS Biotechnology Corp","filed_at":"2025-03-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.721173+00:00","generated_at":"2026-05-25T03:34:04.445060+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"PDS Biotech initiates VERSATILE-003 Phase 3 trial for Versamune HPV in head and neck cancer","bullets":["Phase 3 trial VERSATILE-003 now open to patient enrollment for HPV16-positive head and neck cancer.","Trial to enroll ~350 patients at 2:1 ratio; primary endpoint is overall survival.","First-ever Phase 3 trial in HPV16-positive head and neck cancer.","Versamune HPV already has FDA Fast Track designation based on Phase 2 data."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-007516","json":"https://secwatch.observer/filing/0001140361-25-007516.json","markdown":"https://secwatch.observer/filing/0001140361-25-007516.md","text":"https://secwatch.observer/filing/0001140361-25-007516.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472091/000114036125007516/0001140361-25-007516-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472091/000114036125007516/ef20045063_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T03:34:04.445060+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}